Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P080020/S057

GEL-ONE

Seikagaku Corp. · Decision date Aug 26, 2026

FDA DECISIONP080020/S057

What did the FDA decide?

FDA records P080020/S057 as a supplement to PMA P080020, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 26, 2026.

FDA approval order statement

A change in the manufacturer of the A-PET thermoformed sheet used in blister packaging
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Orthopedic
Decision date
Aug 26, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P080020/S057
Regulatory pathway
PMA supplement
Product code
MOZ
Decision code
OK30
Decision date
Aug 26, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Acid, hyaluronic, intraarticular.

Product code
MOZ
FDA device class
3

For the original device and its historical approval scope, see PMA P080020. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P080020/S057 received

    Application receipt date recorded by FDA.

  2. P080020/S057 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P080020. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P080020

Product / regulatory recordCompanyPathwayDecision dateSource
GEL-ONEP080020
Seikagaku Corp.PMA approvalMar 22, 2011FDA
GEL-ONEP080020/S055
Seikagaku Corp.PMA supplementApr 9, 2026FDA
Gel-OneP080020/S056
Seikagaku Corp.PMA supplementSep 4, 2026FDA

Explore the linked device profile

Other records with product code MOZ

Product / regulatory recordCompanyPathwayDecision dateSource
SUPARTZ FXP980044/S067
Seikagaku Corp.PMA supplementSep 4, 2026FDA
Ferring Pharmaceuticals, Inc.PMA supplementSep 2, 2026FDA
Anika Therapeutics, Inc.PMA supplementAug 28, 2026FDA
SUPARTZ FXP980044/S068
Seikagaku Corp.PMA supplementAug 26, 2026FDA
Gelsyn-3P110005/S015
Ibsa Institut Biochimique SAPMA supplementJul 24, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Seikagaku Corp.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6-1, Marunouchi 1-Chome,, Chiyoda-Ku, Tokyo, 100-0005

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records